Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous induced neural stem cell-derived DA precursor cells
- Development stage
- Phase 1
- Lead developer
- Aspen Neuroscience
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intracerebral, Intrastriatal, Surgical Implantation
01
Overview
Autologous induced neural stem cell-derived DA precursor cells is an experimental cell therapy developed for the treatment of Parkinson's disease. The therapeutic process involves reprogramming a patient's own somatic cells into induced pluripotent stem cells (iPSCs), which are then differentiated in vitro into midbrain dopaminergic progenitor cells (mDAPs) or neural stem cell-derived dopaminergic precursors. These cells are surgically transplanted into the striatum (specifically the putamen) to replace the dopaminergic neurons lost during the progression of the disease. By utilizing autologous cells, the therapy aims to minimize the risk of immune rejection and eliminate the need for long-term immunosuppression. Clinical development is currently in early phases, with studies evaluating safety, cell survival, and motor symptom improvement.
- Other names
- autologous iPSC-derived midbrain dopaminergic progenitor cellsautologous mDAPsautologous iPSC-derived DA precursor cellsautologous induced neural stem cell-derived dopaminergic precursor cells
Beyond the preview
Go deeper on autologous induced neural stem cell-derived DA precursor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous induced neural stem cell-derived DA precursor cells.